Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics, Plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA PRESENTED AT THE 40 TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING THE SPLICEOSOME TARGETING PAYLOAD, PH1, DEMONSTRATES THE ABILITY TO INDUCE BOTH CANCER CELL CYTOTOXICITY AND ACTIVATION OF ANTI-TUMOR IMMUNITY THROUGH MULTIPLE MECHANISMS TREATMENT WITH A TRASTUZUMAB-PH1 ADC MONOTHERAPY DROVE MACROPHAGES TO POLARIZE INTO AN ANTI-TUMOR/INFLAMMATORY STATE AND CAUSED EXPANSION OF B CELL CLONES AND SUBSEQUENT IGM ANTIBODIES WHEN COMBINED WITH ANTI-PD1 THERAPY, ADDITIONAL EFFECTS INCLUDED EXPANSION OF GAMMA-DELTA T CELL CLONES DEMONSTRATING THAT THE COMBINED REGIMEN DRIVES INNATE, ADAPTIVE, AND HUMORAL IMMUNITY AGAINST THE TUMOR IN PRECLINICAL EXPERIMENTS, THE COMBINATION OF TRASTUZUMAB PH1 + ANTI-PD1 OUTPERFORMS THE COMBINATION OF KADCYLA  + ANTI-PD1 WITH A STATISTICALLY SIGNIFICANTLY GREATER RATE OF COMPLETE RESPONSES (74% V 42%, P

AKARI THERAPEUTICS PRESENTS PROMISING IMMUNO-ONCOLOGY DATA FOR ITS NOVEL SPLICING-TARGETED ADC PAYLOAD DRIVING IMMUNE ACTIVATION, BOTH AS SINGLE AGENT AND IN COMBINATION WITH ANTI-PD1 CHECKPOINT INHIBITORS

DATA TO BE PRESENTED AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING ON NOVEMBER 7TH AND 9TH DATA TO BE PRESENTED AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING ON NOVEMBER 7TH AND 9TH

AKARI THERAPEUTICS' ACCEPTED ABSTRACT SHOWCASING ITS NOVEL SPLICING-TARGETED ADC PAYLOAD DRIVING IMMUNE ACTIVATION NOW AVAILABLE

DR. HURVITZ IS AN INTERNATIONAL EXPERT IN ONCOLOGY AND A RECOGNIZED CLINICAL RESEARCH LEADER WITH EXTENSIVE EXPERIENCE LEADING CLINICAL TRIALS SPANNING ALL PHASES DR. HURVITZ IS AN INTERNATIONAL EXPERT IN ONCOLOGY AND A RECOGNIZED CLINICAL RESEARCH LEADER WITH EXTENSIVE EXPERIENCE LEADING CLINICAL TRIALS SPANNING ALL PHASES

AKARI THERAPEUTICS ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD AND INAUGURAL APPOINTMENT OF RENOWNED MEDICAL ONCOLOGIST, SARA A. HURVITZ, MD, FACP

CEO CORNER SEGMENTS TO PROVIDE ADDED PERSPECTIVE TO PRESS RELEASES, CORPORATE DEVELOPMENTS AND PIPELINE PROGRESS PROVIDES INTERESTED PARTIES WITH THE ABILITY TO ASK QUESTIONS AND SUBMIT TOPICS FOR FUTURE VIDEOS ACCESS THE AKARI CEO CORNER HERE BOSTON AND LONDON, OCT. 22, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THE LAUNCH OF ITS CEO CORNER FEATURING ABIZER GASLIGHTWALA, PRESIDENT AND CEO OF AKARI. THE CEO CORNER PLATFORM IS INTENDED TO PROVIDE ADDITIONAL AND IN-DEPTH PERSPECTIVE TO PRESS RELEASES, CORPORATE DEVELOPMENTS AND DEVELOPMENT PIPELINE PROGRESS.

AKARI THERAPEUTICS ANNOUNCES LAUNCH OF CEO CORNER PLATFORM

BOSTON AND LONDON, OCT. 15, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX) (THE COMPANY), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT FOR THE ISSUANCE AND SALE OF AN AGGREGATE OF 3,125,000 OF THE COMPANY'S AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 2,000 ORDINARY SHARES AT A PURCHASE PRICE OF $0.80 PER ADS IN A REGISTERED DIRECT OFFERING. LADENBURG THALMANN & CO. INC. IS ACTING AS THE EXCLUSIVE PLACEMENT AGENT FOR THE OFFERING.

AKARI THERAPEUTICS ANNOUNCES $2.5 MILLION REGISTERED DIRECT OFFERING

BOSTON AND LONDON, OCT. 09, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS FILED TWO NEW PROVISIONAL PATENT APPLICATIONS WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO). THE FIRST APPLICATION INCLUDES CLAIMS PROTECTING AKARI'S NOVEL IMMUNO-ONCOLOGY PAYLOAD, PH1 (A NOVEL THAILANSTATIN ANALOG), AND ITS SPLICEOSOME MODULATORY MECHANISM OF ACTION, WHICH IS EXPECTED TO PROVIDE A THERAPEUTIC BENEFIT BY ACTIVATING THE HOST IMMUNE SYSTEM IN THE FIGHT AGAINST CANCER. THE SECOND PATENT FILING INCLUDES CLAIMS FOR A COMBINATION THERAPY OF PH1 PIPELINE ADCS WITH OTHER IMMUNO-ONCOLOGY DRUGS THAT ALLEVIATE CHECKPOINT INHIBITION AND HAVE DEMONSTRATED SYNERGY WITH IMMUNE CHECKPOINT INHIBITORS (ICIS) IN PRECLINICAL MODELS. THESE NEW PATENT APPLICATIONS ARE PART OF A GROWING PATENT PORTFOLIO STRATEGY DESIGNED TO FURTHER EXTEND AKARI'S PROPRIETARY POSITION WITH RESPECT TO THE COMPANY'S NOVEL PH1 PAYLOAD. THESE FILINGS ALSO BUILD UPON AKARI'S RECENT PROVISIONAL PATENT FILING IN LATE SEPTEMBER COVERING THE USE OF AKARI'S ADC PLATFORM TO TARGET CANCER BY MODULATING ALTERNATIVE SPLICING DRIVERS WITHIN CANCER CELLS.

AKARI THERAPEUTICS FILES TWO NEW PATENTS FOR IMMUNO-ONCOLOGY MODE OF ACTION FOR NOVEL ADC PLATFORM UTILIZING SPLICEOSOME MODULATING PAYLOAD PH1

BOSTON AND LONDON, OCT. 03, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED ITS ABSTRACT HAS BEEN ACCEPTED FOR ORAL PRESENTATION AT THE 40 TH ANNUAL SITC MEETING BEING HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MD.

AKARI THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING

DATA HIGHLIGHTS ABILITY OF AKARI'S ADC PAYLOAD, PH1, TO SUPPRESS THE LEVELS OF THE AR-V7 RECEPTOR THAT IS RESPONSIBLE FOR DRIVING HORMONE REFRACTORY PROSTATE CANCER PROGRESSION

AKARI THERAPEUTICS' PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1

BOSTON AND LONDON, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS FILED A PROVISIONAL PATENT APPLICATION WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) COVERING THE COMPANY'S ANTIBODY DRUG CONJUGATE (ADC) PLATFORM USING AKARI'S SPLICEOSOME PAYLOAD PH1 FOR TREATING CANCER BY MODULATING ALTERNATIVE SPLICING WITHIN CANCER CELLS. THIS PATENT APPLICATION REPRESENTS A NEW PATENT FAMILY TO FURTHER EXTEND AKARI'S PROPRIETARY POSITION WITH RESPECT TO THE COMPANY'S NOVEL PAYLOAD, PH1 (A NOVEL THAILANSTATIN ANALOG).

AKARI THERAPEUTICS ANNOUNCES FILING FOR NEW PATENT FOR NOVEL ADC PLATFORM UTILIZING SPLICEOSOME PAYLOAD PH1 FOR THE TREATMENT OF CANCER

BOSTON AND LONDON, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT ABIZER GASLIGHTWALA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF AKARI THERAPEUTICS WILL PRESENT AT THE H.C. WAINWRIGHT 27 TH ANNUAL GLOBAL INVESTMENT CONFERENCE BEING HELD FROM SEPTEMBER 8-10, 2025 IN NEW YORK, NY.

AKARI THERAPEUTICS TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

LIVE MODERATED WEBCAST ON THURSDAY, SEPTEMBER 4 TH AT 4:00 PM ET ACCESS THE EVENT HERE BOSTON AND LONDON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL IMMUNO-ONCOLOGY PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE VIRTUAL INVESTOR CLOSING BELL SERIES ON THURSDAY, SEPTEMBER 4, 2025 AT 4:00 PM ET.

Akari Therapeutics, Plc

AKTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Akari Therapeutics, Plc

AKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AKTX